ZHAN Xiao-jing,LI Min,ZOU Jian-jun,BWIRE Robert,LONDON Calvin. First Risk Minimization Program for Preventing Foetal Exposure of Revlimid in China[J]. Chinese Journal of Pharmacovigilance, 2015, 12(12): 735-739.
[1] Miller M T, Stromland K. Teratogen update: thalidomide: a review, with a focus on ocular findings and new potential uses[J]. Teratology, 1999, 60(5): 306-321. [2] Uhl K, Cox E, Rogan R, et al. Thalidomide Use in the US: Experience with Pregnancy Testing in the S.T.E.P.S. Programme[J]. Drug Saf, 2006, 29 (4): 321 - 329. [3] US Food and Drug Administration. Food and Drug Administration Amendments Act of 2007[EB/OL]. (2007-09-27)[2015-06-29]. http://www.gpo.gov/fdsys/pkg/PLAW-110publ85/pdf/PLAW- 110publ85.pdf. [4] European Medicines Agency.Guideline on risk assessment of medi- cinal products on human reproduction and lactation: from data to 5 labeling[EB/OL]. (2008-07-24)[2015-06-29]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/ 6 2009/09/WC500003307.pdf. [5] Witty J M, Thompson M, Freeman J, et al. Assessment of the Effectiveness of the Thalidomide Celgene Pregnancy Prevention Programme (PPP) in the United Kingdom[J]. Drug Saf, 2010, 33(10): 19-19. [6] Bwire R, Freeman J, Houn F. Managing the teratogenic risk of thalidomide and lenalidomide: an industry perspective[J]. Expert Opin Drug Saf, 2011, 10(1): 3-8. [7] Brum L, Laplaza D, Kaehler S T, et al. Effectiveness Assessment Survey of the Spanish Risk Management Plan for Lenalidomide[J]. Drug Saf, 2011, 34(10): 904- 905.